Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 14;13:848630. doi: 10.3389/fimmu.2022.848630

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Serrano-Villar, López-Huertas, Jiménez, Galera, Martínez-Sanz, Moreno, Muriel, Gutiérrez, Busca, Portilla, Bisbal, Iribarren, Tejerina, de los Santos and Moreno

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Effects of switch to 2-drug regimens (2DR), segregated by the type of 2DR regimen, on inflammatory biomarkers compared to remaining on 3-drug regimens (3DR). Panels represent the values predicted in piecewise linear mixed models at intervals between years 0-1, 1-2, 2-3, 3-4 and 4-8, adjusted for age, sex, country of origin, mode of transmission, educational level, maximum HIV RNA, previous AIDS, nadir CD4, and pre-ART biomarker value. Lines represent predicted mean values and dots the individual observations. Abbreviatures, 3DR, 3-drug regimens; 2DR-PI, protease inhibitor 2-drug regimens; 2DR-DTG, dolutegravir-based 2-drug regimens.